Are you Dr. Chakravarthy?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 55 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
1 Robert Wood Johnson Pl
# MEB384
New Brunswick, NJ 08901Phone+1 732-235-7749Fax+1 314-747-8963
Summary
- Dr. Manu Chakravarthy, MD is an endocrinologist in New Brunswick, New Jersey. He is currently licensed to practice medicine in New Jersey, Missouri, and Pennsylvania.
Education & Training
Washington University/B-JH/SLCH ConsortiumFellowship, Endocrinology, Diabetes, and Metabolism, 2003 - 2006
University of Pennsylvania Health SystemResidency, Internal Medicine, 2001 - 2003
McGovern Medical School at UTHealthClass of 2001
Certifications & Licensure
NJ State Medical License 2009 - 2025
MO State Medical License 2006 - 2016
PA State Medical License 2001 - 2003
Publications & Presentations
PubMed
- 141 citationsExercise and gene expression: physiological regulation of the human genome through physical activityFrank W. Booth, Manu V. Chakravarthy, Espen E. Spangenburg
The Journal of Physiology. 2002-09-01 - 85 citationsErratum: Acetyl CoA Carboxylase Inhibition Reduces Hepatic Steatosis but Elevates Plasma Triglycerides in Mice and Humans: A Bedside to Bench Investigation (Cell Metab...Chai Wan Kim, Carol Addy, Jun Kusunoki, Norma N. Anderson, Stanislaw Deja
Cell Metabolism. 2017-09-05 - 410 citationsNew hepatic fat activates PPARalpha to maintain glucose, lipid, and cholesterol homeostasisManu V. Chakravarthy, Zhijun Pan, Yimin Zhu, Karen Tordjman, Jochen G. Schneider
Cell Metabolism. 2005-05-01
Press Mentions
Carmot Therapeutics Announces Investigational New Drug (IND) Clearance for CT-868, a Dual GLP-1 and GIP Receptor Modulator for the Treatment of Overweight and Obese Patients with Type 2 DiabetesMay 4th, 2021- Carmot Therapeutics Expands Leadership Team with Appointment of Manu Chakravarthy, MD, PhD as Chief Medical Officer and Executive Vice President of R&DMarch 17th, 2021
- Axcella Announces IND Clearance for AXA1665, Program Updates and 2021 MilestonesJanuary 11th, 2021
- Join now to see all
Grant Support
- Identification Of The Physiologically Relevant Endogenous Ligand For Ppar?National Center For Research Resources2009–2011
- ?New" Hepatic Fat Activates Ppar? To Maintain Glucose, Lipid, And CholesterolNational Center For Research Resources2007
- New Hepatic Fat Activates Ppara To Maintain Glucose Lipid Cholesterol HomeoNational Center For Research Resources2006–2007
